Table 2.

Past, present, and future clinical trials using ribavirin in cancer

Clinical trialsID numberStatus as of December 2018ConditionTreatmentPhaseReferences
Low-dose Peg-interferon plus ribavirin (IFN/RBV) for prevention of hepatocellular carcinoma (HCC) recurrence in patients who had surgery to remove primary HCCNCT00375661CompletedHepatocellular carcinomaInterferon-alfa-2b, ribavirin4NA
A study of ribavirin to treat M4 and M5 acute myelocytic leukemiaNCT00559091CompletedAcute myeloid leukemiaRibavirin2(6)
Effect of biological therapy on biomarkers in patients with untreated hepatitis C, metastatic melanoma, or Crohn diseaseNCT00897312TerminatedMelanomaInfliximab, pegylated-interferon alfa, ticilimumab, ribavirinNANA
Use of ribavirin and low-dose ara-C to treat acute myeloid leukemiaNCT01056523Completed (has results)Acute myeloid leukemiaRibavirin, cytarabine arabinoside1–2(6, 7)
Treatment with ribavirin for patients with metastatic breast cancerNCT01056757TerminatedBreast cancerRibavirin1–2NA
Peg-interferon plus ribavirin for hepatitis C patients concomitant with hepatocellular carcinomaNCT00834860UnknownHepatocellular carcinomaPeg-interferon alpha-2a, ribavirin4(26)
Phase I/II study of ribavirin given as monotherapy in solid tumor cancer patientsNCT01309490UnknownMalignant solid tumorRibavirin1–2NA
Ribavirin and Hedgehog inhibitor with or without decitabine in AMLNCT02073838RecruitingAcute myeloid leukemiaRibavirin, Hedegehog inhibitor, decitabine2NA
Study of decitabine in combination with sequential rapamycin or ribavirin in high-risk AML patients (AML)NCT02109744RecruitingAcute myeloid leukemiaDecitabine, rapamycin, ribavirin1–2NA
Oral hepatitis C treatment for indolent lymphoma (OPTImaL) study (Optimal)NCT02717949Terminated (results submitted)LymphomaSofosbuvir, ledipasvir, ribavirin4NA
Impact of interferon free regimens in patients with chronic HCV and successfully treated HCC (FRI-STC)NCT02771405RecruitingHepatocellular carcinomaSofosbuvir, ribavirin, simeprevir, daclatasvir, ledipasvir3(29)
Sofosbuvir + ledipasvir ± ribavirin and sofosbuvir + ribavirin for pts with indolent B-cell lymphoma associated with HCV infectionNCT02836925RecruitingB-Cell lymphomaSofosbuvir, ledipasvir, ribavirin2NA
Pharmacodynamic effects of ribavirin in patients with tonsil and/or base of tongue squamous cell carcinomaNCT01268579Active, not recruitingHead and neck cancerRibavirinNANA
Induction chemotherapy with afatinib, ribavirin, and weekly carboplatin/paclitaxel for stage IVA/IVB HPV-associated oropharynx squamous cell cancer (OPSCC)NCT01721525CompletedHead and neck cancerAfatinib, ribavirin, carboplatin/paclitaxel1(15)
Peg-interferon plus ribavirin for hepatitis C patients concomitant with malignancy other than hepatocellular carcinomaNCT00630084CompletedNeoplasmsPeg-interferon alpha-2a, ribavirin4NA
A pilot investigator-initiated study of ribavirin in indolent follicular lymphoma and mantle cell lymphomaNCT03585725RecruitingFollicular/mantle cell lymphomaRibavirin1NA
A clinical study to evaluate the efficacy and safety of docetaxel with ribavirin in patients with progressive castration-resistant prostate cancer who have previously received docetaxel aloneUMIN 000012521CompletedCastration-resistant prostate cancerRibavirin, docetaxel1–2(43)
A phase 1/2a trial of docetaxel plus ribavirin for reprogramming efficacy in patients with progressive metastatic castration-resistant prostate cancer who previously received docetaxel alone: DRREEM trialUMIN 000021107CompletedCastration-resistant prostate cancerRibavirin, docetaxel1–2(46)
Ribavirin for patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-related malignanciesNCT02308241Active, not recruitingHPV-Related malignanciesRibavirinNANA